Duration of palliative care involvement and immunotherapy treatment near the end of life among patients with cancer who died in-hospital-Reference-Cited by-同舟云学术

Duration of palliative care involvement and immunotherapy treatment near the end of life among patients with cancer who died in-hospital

Published:2022-02-22 Issue:6 Volume:30 Page:4997-5006
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Auclair Juline,Sanchez Stéphane,Chrusciel Jan,Hannetel Louise,Frasca Matthieu,Economos Guillaume,Habert-Dantigny Raphaelle,Bruera Eduardo,Burucoa Benoit,Ecarnot Fiona,Colombet Isabelle,Barbaret Cécile^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-022-06901-1.pdf

Reference38 articles.

1. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12 https://doi.org/10.3390/cancers12030738.

2. Davis MP, Panikkar R (2018) Checkpoint inhibitors, palliative care, or hospice. Curr Oncol Rep 20:2. https://doi.org/10.1007/s11912-018-0659-0

3. Magee DE, Hird AE, Klaassen Z, Sridhar SS, Nam RK, Wallis CJD, Kulkarni GS (2020) Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol 31:50–60. https://doi.org/10.1016/j.annonc.2019.10.008

4. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742. https://doi.org/10.1056/NEJMoa1000678

5. Vanbutsele G, Pardon K, Van Belle S, Surmont V, De Laat M, Colman R, Eecloo K, Cocquyt V, Geboes K, Deliens L (2018) Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol 19:394–404. https://doi.org/10.1016/S1470-2045(18)30060-3

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US;JAMA Oncology;2024-03-01

2. “There is No Alternative.” Treatment Decision‐Making in Lung Cancer Patients with Limited Prognosis: Results of a Qualitative Interview Study;European Journal of Cancer Care;2024-01

3. Increasing challenges of general practitioner-oncologist interaction in end-of-life communication: a qualitative study;2023-08-10

4. The Cost of Cancer Care at the End of Life: Implications for Centers for Medicare and Medicaid Services and for Radiation Oncology;International Journal of Radiation Oncology*Biology*Physics;2023-07

5. Challenges of general practitioner-oncologist interaction in end-of-life communication: a qualitative study;2023-03-13